Back to search results

Predictors of Health-Related Quality of Life in CLL or SLL

This study is looking at how your quality of life, fatigue, and other symptoms change over two years if you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and are starting treatment. Researchers are comparing two types of treatment: Bruton's tyrosine kinase inhibitors (BTKi) or B-Cell Lymphoma 2 Protein Inhibitors (BCL2i) with Obinutuzumab. The goal is to understand what predicts your health-related quality of life (HRQOL) and how treatments affect it, which can help future patients know what to expect. You can join if you are 18 or older, have a confirmed diagnosis of CLL, and are starting one of these treatments within seven days. The study is currently unclear on its recruitment status and aims to enroll 100 participants.

Study design
This is an observational study, meaning researchers will watch and collect information without giving you a specific treatment. It plans to include 100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health-related quality of life and its predictors will be measured for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07030400

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Recruiting
Not specifiedAges 18+Observational
H. Lee Moffitt Cancer Center and Research Institute
~100 participants
Updated 2026-04-01 on ClinicalTrials.gov
What's tested:Bruton's tyrosine kinase inhibitorB-Cell Lymphoma 2 Protein Inhibitor

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Health Related Quality of Life (HRQOL)
Measured over Up to 2 years
+2 more outcomes measured

Conditions

Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia (CLL)

Explore related trials

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Sara Tinsley-Vance, PhD, APRN, AOCN · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center

Who to contact

Daniel Lastorino
[email protected]
813-745-0092
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
Subjects must be able to read and speak English or Spanish at the 8th grade level.

Exclusion

Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.

What this trial measures

  • Health Related Quality of Life (HRQOL)Up to 2 years

    Compare the differences in HRQOL scores measured by the Functional Assessment of Cancer Therapy Leukemia version for patients receiving BTKi, and BCL2i within 7 days of beginning treatment and at days 30,60, 90, 180, 1 year, 1.5 years, and 2 years following initiation of treatment.

  • HRQOL predictorsUp to 2 years

    Investigators will test how age, comorbidity, fatigue, symptoms, and disease characteristics are related to the slope of HRQOL in separate models.

  • Interactions with treatmentUp to 2 years

    Three models will assess interactions between treatment and age, comorbidity, and fatigue.